fulvestrant has been researched along with vorinostat in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Lin, X; Luo, G; Ma, L; Ren, S; Wang, X; Wu, S; Xiang, H | 1 |
| Aranda, A; De los Santos, M; MartÃnez-Iglesias, O | 1 |
1 review(s) available for fulvestrant and vorinostat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for fulvestrant and vorinostat
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Development; Drug Screening Assays, Antitumor; Estrogen Receptor alpha; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Structure-Activity Relationship; Tetrahydroisoquinolines; Tumor Cells, Cultured | 2021 |
Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Butyrates; Cell Line, Tumor; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Polymerase Chain Reaction; RNA, Neoplasm; Vorinostat | 2007 |